NTLA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.10%

Insider Buying (Last 12 Months): $1,003,000.00

Insider Selling (Last 12 Months): $541,697.15

Intellia Therapeutics Insider Trading History Chart

Intellia Therapeutics Share Price & Price History

^$9.74

▲ +0.68 (7.51%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Intellia Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/1/2025	Birgit C Schultes	EVP	Sell	31	$17.38	$538.78	105,184
10/1/2025	Michael P Dube	CAO	Sell	1,871	$17.38	$32,517.98	55,266
8/20/2025	William J. Chase	Director	Buy	100,000	$10.03	$1,003,000.00	134,693
7/23/2025	J Dulac III	EVP	Sell	7,462	$14.02	$104,617.24	106,062
7/2/2025	Michael P Dube	CAO	Sell	2,503	$9.95	$24,904.85	57,137
7/1/2025	Eliana Clark	EVP	Sell	1,022	$9.82	$10,036.04	95,369
7/1/2025	Jesse Goodman	Director	Sell	1,547	$9.23	$14,278.81	24,359
4/29/2025	Muna Bhanji	Director	Sell	265	$8.50	$2,252.50	19,203
1/29/2025	Muna Bhanji	Director	Sell	265	$9.97	$2,642.05	19,468
1/3/2025	John M Leonard	CEO	Sell	26,807	$12.18	$326,509.26	941,115
1/3/2025	Michael P Dube	CAO	Sell	1,372	$12.18	$16,710.96	45,640
1/2/2025	Eliana Clark	EVP	Sell	556	$12.03	$6,688.68	71,470
10/2/2024	Michael P Dube	CAO	Sell	2,012	$19.01	$38,248.12	47,012
7/1/2024	Eliana Clark	EVP	Sell	405	$22.93	$9,286.65	71,470
3/4/2024	James Basta	EVP	Sell	2,297	$32.99	$75,778.03	81,571
1/8/2024	Laura Sepp-Lorenzino	EVP	Sell	2,275	$28.87	$65,679.25	43,927
1/3/2024	David Lebwohl	EVP	Sell	5,843	$29.46	$172,134.78	54,372
1/3/2024	Glenn Goddard	CFO	Sell	5,365	$29.46	$158,052.90	40,585
1/3/2024	John M Leonard	CEO	Sell	19,223	$29.46	$566,309.58	846,486
10/31/2023	Muna Bhanji	Director	Sell	265	$23.90	$6,333.50	11,996
7/31/2023	Muna Bhanji	Director	Sell	265	$42.33	$11,217.45	12,261
7/6/2023	Muna Bhanji	Director	Sell	1,867	$39.30	$73,373.10	12,526
7/3/2023	Eliana Clark	EVP	Sell	360	$40.51	$14,583.60	45,146
6/20/2023	Eliana Clark	EVP	Sell	5,000	$45.00	$225,000.00	45,146
1/4/2023	Glenn Goddard	CFO	Sell	2,427	$37.21	$90,308.67	15,404
1/4/2023	John M Leonard	CEO	Sell	6,673	$37.21	$248,302.33	766,825
1/4/2023	Laura Sepp-Lorenzino	EVP	Sell	2,508	$37.21	$93,322.68	19,959

SEC Filings (Institutional Ownership Changes) for Intellia Therapeutics (NASDAQ:NTLA)

88.77% of Intellia Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intellia Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/21/2025	CIBC Bancorp USA Inc.	10,585	$0.18M	0.0%	N/A	0.009%
11/19/2025	Danske Bank A S	2,900	$50K	0.0%	N/A	0.003%
11/19/2025	Caitong International Asset Management Co. Ltd	1,749	$30K	0.0%	N/A	0.002%
11/18/2025	Advisory Services Network LLC	1,889	$33K	0.0%	N/A	0.002%
11/17/2025	Kestra Private Wealth Services LLC	35,208	$0.61M	0.0%	N/A	0.030%
11/17/2025	Armistice Capital LLC	672,000	$11.61M	0.2%	+3.4%	0.580%
11/17/2025	CANADA LIFE ASSURANCE Co	25,027	$0.42M	0.0%	+15.1%	0.022%
11/17/2025	Woodline Partners LP	200,998	$3.47M	0.0%	-83.5%	0.174%
11/17/2025	PDT Partners LLC	156,804	$2.71M	0.2%	-20.2%	0.135%
11/17/2025	Dark Forest Capital Management LP	10,558	$0.18M	0.0%	-71.1%	0.009%
11/17/2025	Voloridge Investment Management LLC	1,610,205	$27.81M	0.1%	+3.7%	1.390%
11/17/2025	Verition Fund Management LLC	32,297	$0.56M	0.0%	-70.3%	0.028%
11/17/2025	Steadfast Capital Management LP	365,400	$6.31M	0.1%	N/A	0.315%
11/17/2025	Scientech Research LLC	28,087	$0.49M	0.2%	N/A	0.024%
11/17/2025	Sherbrooke Park Advisers LLC	20,898	$0.36M	0.2%	+14.3%	0.018%
11/17/2025	Northwestern Mutual Wealth Management Co.	7,080	$0.12M	0.0%	+38.6%	0.006%
11/17/2025	Millennium Management LLC	607,563	$10.49M	0.0%	-26.9%	0.525%
11/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	120,415	$2.08M	0.0%	-7.0%	0.104%
11/17/2025	Granahan Investment Management LLC	342,586	$5.92M	0.2%	-62.5%	0.296%
11/17/2025	Farallon Capital Management LLC	607,200	$10.49M	0.0%	N/A	0.524%
11/17/2025	Fred Alger Management LLC	51,790	$0.89M	0.0%	N/A	0.045%
11/17/2025	Brevan Howard Capital Management LP	64,154	$1.11M	0.0%	+190.3%	0.055%
11/17/2025	Baker BROS. Advisors LP	2,746,674	$47.44M	0.3%	+2.7%	2.371%
11/17/2025	Bank of America Corp DE	605,526	$10.46M	0.0%	+41.1%	0.523%
11/17/2025	Ameriprise Financial Inc.	49,647	$0.86M	0.0%	+320.6%	0.043%
11/14/2025	Schonfeld Strategic Advisors LLC	18,447	$0.32M	0.0%	N/A	0.016%
11/14/2025	Creative Planning	35,733	$0.62M	0.0%	+7.9%	0.031%
11/14/2025	Lazard Asset Management LLC	114,614	$1.98M	0.0%	+24.0%	0.099%
11/14/2025	Raymond James Financial Inc.	316,950	$5.47M	0.0%	+6.1%	0.274%
11/14/2025	Zurcher Kantonalbank Zurich Cantonalbank	53,603	$0.93M	0.0%	+51.7%	0.046%
11/14/2025	UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC	241,282	$4.17M	0.0%	-62.2%	0.208%
11/14/2025	Tower Research Capital LLC TRC	63,509	$1.10M	0.0%	+20.1%	0.055%
11/14/2025	Two Sigma Investments LP	2,449,607	$42.31M	0.1%	+7.6%	2.115%
11/13/2025	Jump Financial LLC	275,992	$4.77M	0.0%	-39.6%	0.238%
11/13/2025	Kennedy Capital Management LLC	26,514	$0.46M	0.0%	+96.3%	0.023%
11/13/2025	Invesco Ltd.	409,420	$7.07M	0.0%	+62.7%	0.353%
11/13/2025	Sei Investments Co.	34,751	$0.60M	0.0%	+32.3%	0.030%
11/13/2025	BNP Paribas Financial Markets	50,251	$0.87M	0.0%	-88.2%	0.043%
11/13/2025	Franklin Resources Inc.	10,239	$0.18M	0.0%	N/A	0.009%
11/13/2025	Swiss National Bank	190,700	$3.29M	0.0%	+1.8%	0.165%
11/13/2025	Russell Investments Group Ltd.	11,308	$0.20M	0.0%	+747.0%	0.010%
11/13/2025	Pinnacle Associates Ltd.	163,710	$2.83M	0.0%	-3.3%	0.141%
11/13/2025	Blair William & Co. IL	20,160	$0.35M	0.0%	N/A	0.017%
11/12/2025	Aptus Capital Advisors LLC	71,481	$1.23M	0.0%	-5.0%	0.062%
11/12/2025	Orchard Capital Management LLC	81,598	$1.41M	1.2%	+3.0%	0.070%
11/12/2025	Barclays PLC	488,226	$8.43M	0.0%	-5.8%	0.422%
11/12/2025	Amova Asset Management Americas Inc.	2,354,856	$40.62M	0.4%	-11.8%	2.033%
11/12/2025	ARK Investment Management LLC	11,919,178	$205.84M	1.2%	-8.4%	10.290%
11/12/2025	Dimensional Fund Advisors LP	1,757,294	$30.35M	0.0%	-5.8%	1.517%
11/12/2025	Contrarius Group Holdings Ltd	5,889,936	$101.72M	4.6%	+279.4%	5.085%
11/12/2025	Creekmur Asset Management LLC	38,677	$0.67M	0.1%	-34.0%	0.033%
11/12/2025	Rafferty Asset Management LLC	183,091	$3.16M	0.0%	+42.2%	0.158%
11/12/2025	Erste Asset Management GmbH	23,100	$0.39M	0.0%	-72.9%	0.020%
11/12/2025	R Squared Ltd	10,782	$0.19M	0.1%	N/A	0.009%
11/12/2025	Interchange Capital Partners LLC	11,695	$0.20M	0.0%	+9.7%	0.010%
11/12/2025	IvyRock Asset Management HK Ltd	14,330	$0.25M	0.1%	N/A	0.012%
11/12/2025	Intech Investment Management LLC	44,587	$0.77M	0.0%	-22.2%	0.038%
11/12/2025	US Bancorp DE	1,965	$34K	0.0%	-36.9%	0.002%
11/10/2025	Ameritas Investment Partners Inc.	8,295	$0.14M	0.0%	-15.0%	0.008%
11/10/2025	Vestmark Advisory Solutions Inc.	297,566	$5.14M	0.1%	-53.4%	0.277%
11/10/2025	China Universal Asset Management Co. Ltd.	38,816	$0.67M	0.1%	+86.6%	0.036%
11/10/2025	Jupiter Asset Management Ltd.	1,361,849	$23.52M	0.2%	N/A	1.269%
11/7/2025	Readystate Asset Management LP	74,266	$1.28M	0.1%	N/A	0.069%
11/7/2025	Axxcess Wealth Management LLC	17,816	$0.31M	0.0%	+11.5%	0.017%
11/7/2025	NEOS Investment Management LLC	14,720	$0.25M	0.0%	-38.8%	0.014%
11/7/2025	GSA Capital Partners LLP	75,091	$1.30M	0.1%	-59.3%	0.070%
11/7/2025	Vanguard Group Inc.	11,044,820	$190.74M	0.0%	+1.8%	10.289%
11/7/2025	Shell Asset Management Co.	1,563	$27K	0.0%	-96.6%	0.001%
11/6/2025	Whipplewood Advisors LLC	1,600	$28K	0.0%	-53.6%	0.001%
11/6/2025	Elmwood Wealth Management Inc.	78,059	$1.35M	0.5%	+14.9%	0.073%
11/6/2025	Caprock Group LLC	10,682	$0.18M	0.0%	N/A	0.010%
11/6/2025	Rhumbline Advisers	159,479	$2.75M	0.0%	-2.9%	0.149%
11/6/2025	Profund Advisors LLC	39,586	$0.68M	0.0%	+43.9%	0.037%
11/6/2025	ProShare Advisors LLC	20,803	$0.36M	0.0%	-16.8%	0.019%
11/6/2025	Oppenheimer & Co. Inc.	104,357	$1.80M	0.0%	-1.7%	0.097%
11/5/2025	IQ EQ FUND MANAGEMENT IRELAND Ltd	494,468	$8.54M	0.6%	+68.0%	0.461%
11/5/2025	Envestnet Asset Management Inc.	86,177	$1.49M	0.0%	+24.2%	0.080%
11/4/2025	Jones Financial Companies Lllp	25,734	$0.42M	0.0%	+38.3%	0.024%
11/3/2025	AlphaQuest LLC	15,876	$0.27M	0.0%	-28.5%	0.015%
11/3/2025	Federated Hermes Inc.	3,263	$56K	0.0%	+39.7%	0.003%
11/3/2025	Generali Investments Towarzystwo Funduszy Inwestycyjnych	80,000	$1.38M	0.7%	-20.0%	0.075%
10/31/2025	Y Intercept Hong Kong Ltd	137,290	$2.37M	0.1%	N/A	0.128%
10/30/2025	Grandfield & Dodd LLC	50,790	$0.88M	0.0%	+4.3%	0.047%
10/30/2025	Universal Beteiligungs und Servicegesellschaft mbH	113,438	$1.96M	0.0%	+74.5%	0.106%
10/28/2025	Nwam LLC	10,500	$0.18M	0.0%	N/A	0.010%
10/27/2025	GWN Securities Inc.	12,624	$0.22M	0.1%	N/A	0.012%
10/27/2025	Sumitomo Mitsui Trust Group Inc.	2,354,856	$40.67M	0.0%	-11.8%	2.194%
10/23/2025	Benjamin Edwards Inc.	64,850	$1.12M	0.0%	+2.9%	0.060%
10/23/2025	SG Americas Securities LLC	131,070	$2.26M	0.0%	+239.7%	0.122%
10/23/2025	KLP Kapitalforvaltning AS	26,600	$0.46M	0.0%	+47.8%	0.025%
10/22/2025	Hennion & Walsh Asset Management Inc.	150,393	$2.60M	0.1%	-1.8%	0.140%
10/22/2025	Blue Bell Private Wealth Management LLC	1,757	$30K	0.0%	N/A	0.002%
10/22/2025	D.A. Davidson & CO.	64,220	$1.11M	0.0%	+18.7%	0.060%
10/20/2025	VIRGINIA RETIREMENT SYSTEMS ET Al	16,742	$0.29M	0.0%	-5.6%	0.016%
10/20/2025	Lewis Asset Management LLC	24,540	$0.42M	0.2%	-31.5%	0.023%
10/15/2025	CWM LLC	19,187	$0.33M	0.0%	+4.7%	0.018%
10/10/2025	Cyndeo Wealth Partners LLC	11,710	$0.20M	0.0%	+9.3%	0.011%
10/9/2025	Voya Investment Management LLC	153,456	$2.65M	0.0%	-42.5%	0.143%
9/4/2025	Osaic Holdings Inc.	20,064	$0.19M	0.0%	+13.4%	0.019%
8/19/2025	Newbridge Financial Services Group Inc.	5,500	$52K	0.0%	N/A	0.005%

Data available starting January 2016

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $9.74

$8.85

$9.92

50 Day Range

MA: $15.47

$8.04

$27.98

52 Week Range

Now: $9.74

$5.90

$28.25

Volume

5,893,115 shs

Average Volume

6,755,643 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13

Who are the company insiders with the largest holdings of Intellia Therapeutics?: Intellia Therapeutics' top insider investors include:
John M Leonard (CEO)
William J Chase (Director)
Edward J Dulac III (EVP)
Birgit C Schultes (EVP)
Eliana Clark (EVP)
James Basta (EVP)
Michael P Dube (CAO)
David Lebwohl (EVP)
Laura Sepp-Lorenzino (EVP)
Glenn Goddard (CFO)
Jesse Goodman (Director)
Muna Bhanji (Director)
Learn More about top insider investors at Intellia Therapeutics.
Who are the major institutional investors of Intellia Therapeutics?: Intellia Therapeutics' top institutional shareholders include:
ARK Investment Management LLC — 10.29%
Vanguard Group Inc. — 10.29%
Contrarius Group Holdings Ltd — 5.08%
Baker BROS. Advisors LP — 2.37%
Two Sigma Investments LP — 2.11%
Sumitomo Mitsui Trust Group Inc. — 2.19%
Learn More about top institutional investors of Intellia Therapeutics stock.
Which institutional investors are selling Intellia Therapeutics stock?: Within the previous quarter, NTLA stock was sold by these institutional investors:
ARK Investment Management LLC
Woodline Partners LP
Granahan Investment Management LLC
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC
BNP Paribas Financial Markets
Vestmark Advisory Solutions Inc.
Sumitomo Mitsui Trust Group Inc.
Amova Asset Management Americas Inc.
In the previous year, company insiders that have sold Intellia Therapeutics company stock include:
John M Leonard (CEO)
William J Chase (Director)
Edward J Dulac III (EVP)
Birgit C Schultes (EVP)
Eliana Clark (EVP)
James Basta (EVP)
Michael P Dube (CAO)
Learn More investors selling Intellia Therapeutics stock.
Which institutional investors are buying Intellia Therapeutics stock?: Within the last quarter, NTLA stock was purchased by institutional investors including:
Contrarius Group Holdings Ltd
Jupiter Asset Management Ltd.
Farallon Capital Management LLC
Steadfast Capital Management LP
Susquehanna International Group LLP
IQ EQ FUND MANAGEMENT IRELAND Ltd
Vanguard Group Inc.
Bank of America Corp DE